[go: up one dir, main page]

DK4288036T3 - Formuleringer af en plasmakallikreinhæmmer - Google Patents

Formuleringer af en plasmakallikreinhæmmer Download PDF

Info

Publication number
DK4288036T3
DK4288036T3 DK23722929.9T DK23722929T DK4288036T3 DK 4288036 T3 DK4288036 T3 DK 4288036T3 DK 23722929 T DK23722929 T DK 23722929T DK 4288036 T3 DK4288036 T3 DK 4288036T3
Authority
DK
Denmark
Prior art keywords
formulations
plasma kallikrein
kallikrein inhibitor
inhibitor
plasma
Prior art date
Application number
DK23722929.9T
Other languages
English (en)
Inventor
John Alexander Cooper
Oliver William Croadshaw
Matthew Scott Iverson
Serena Schiano
Michael David Smith
Ana Catalina Ferreira Arroyo
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK4288036T3 publication Critical patent/DK4288036T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK23722929.9T 2022-04-27 2023-04-27 Formuleringer af en plasmakallikreinhæmmer DK4288036T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263335387P 2022-04-27 2022-04-27
PCT/GB2023/051120 WO2023209381A1 (en) 2022-04-27 2023-04-27 Formulations of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
DK4288036T3 true DK4288036T3 (da) 2024-08-26

Family

ID=86330823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK23722929.9T DK4288036T3 (da) 2022-04-27 2023-04-27 Formuleringer af en plasmakallikreinhæmmer

Country Status (25)

Country Link
US (1) US20250281397A1 (da)
EP (2) EP4480545A3 (da)
JP (1) JP2025514861A (da)
KR (1) KR20250002615A (da)
CN (1) CN119095589A (da)
AU (1) AU2023262237A1 (da)
CA (1) CA3255900A1 (da)
CL (1) CL2024003252A1 (da)
CO (1) CO2024014871A2 (da)
DK (1) DK4288036T3 (da)
ES (1) ES2991820T3 (da)
FI (1) FI4288036T3 (da)
HR (1) HRP20241160T1 (da)
HU (1) HUE068435T2 (da)
IL (1) IL316435A (da)
LT (1) LT4288036T (da)
MA (1) MA63248B1 (da)
MD (1) MD4288036T2 (da)
MX (1) MX2024013084A (da)
PL (1) PL4288036T3 (da)
PT (1) PT4288036T (da)
RS (1) RS66161B1 (da)
SI (1) SI4288036T1 (da)
SM (1) SMT202400372T1 (da)
WO (1) WO2023209381A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
WO2014188211A1 (en) 2013-05-23 2014-11-27 Kalvista Pharmaceuticals Limited Heterocyclic derivates
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
TW202228686A (zh) * 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療

Also Published As

Publication number Publication date
KR20250002615A (ko) 2025-01-07
WO2023209381A1 (en) 2023-11-02
CL2024003252A1 (es) 2025-02-14
JP2025514861A (ja) 2025-05-09
MD4288036T2 (ro) 2025-02-28
MX2024013084A (es) 2024-12-06
HRP20241160T1 (hr) 2024-11-22
CN119095589A (zh) 2024-12-06
HUE068435T2 (hu) 2024-12-28
SI4288036T1 (sl) 2024-10-30
LT4288036T (lt) 2024-09-25
IL316435A (en) 2024-12-01
AU2023262237A1 (en) 2024-10-31
CA3255900A1 (en) 2023-11-02
EP4288036A1 (en) 2023-12-13
ES2991820T3 (es) 2024-12-05
FI4288036T3 (fi) 2024-08-29
EP4480545A3 (en) 2025-02-26
EP4288036B1 (en) 2024-08-07
EP4480545A2 (en) 2024-12-25
PT4288036T (pt) 2024-10-23
MA63248B1 (fr) 2024-11-29
SMT202400372T1 (it) 2024-11-15
CO2024014871A2 (es) 2024-12-09
US20250281397A1 (en) 2025-09-11
PL4288036T3 (pl) 2024-11-25
RS66161B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
DK4288036T3 (da) Formuleringer af en plasmakallikreinhæmmer
EP3984999A4 (en) ALLOSTERIC INHIBITOR OF PHOSPHATASE SHP2
IL318420A (en) Kras inhibitors
DK3999038T3 (da) Orale formuleringer af en kardial sarcomer-inhibitor
EP4211200A4 (en) ENGRAVING COMPOSITIONS
IL315027A (en) Inhibitors of nlrp3
EP4362933A4 (en) COMPLEMENT INHIBITION
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
EP4125884A4 (en) COMBINATIONS OF EIF4A INHIBITORS
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
EP4330769A4 (en) PLASMA ETCHING OF MASK MATERIALS
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
CL2022002112S1 (es) Sustrato
EP4108666A4 (en) MULTI-TARGETED TYROSINE KINASE INHIBITOR
ECSP22016209A (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
IL289214A (en) Crystalline forms of plasma kallikrein inhibitors
DK3980001T3 (da) Depotsammensætninger af alfa-ketoglutarat
DK3974774T3 (da) Opmåling af byggegrube
IL318607A (en) Plasma kallikrein inhibitors
DK4387730T3 (da) Faste former af en rock-hæmmer
DK4192813T3 (da) Inhibitorer af transglutaminaser
EP4416233A4 (en) ENGRAVING COMPOSITIONS
IL320954A (en) Solid dosage forms of plasma kallikrein inhibitor
GB202101735D0 (en) Solid forms of a plasma kallikrein inhibitor and salts thereof